环磷酰胺、吗替麦考酚酯治疗难治性肾病综合征的药物经济学分析

Cyclophamide vs. Mycophenolate Mofetil in the Treatment of Refractory Nephrotic Syndrome:Pharmacoeconomic Analysis

目的:主要比较环磷酰胺、吗替麦考酚酯治疗难治性肾病综合征的用药方案的疗效,评价分析2种方案的成本-效果。方法:将36例患者按随机双盲法分成2组,通过对A组(泼尼松龙+环磷酰胺)、B组[泼尼松龙+吗替麦考酚酯分散片(赛可平)]2种方案治疗难治性肾病综合征的疗效观察,运用药物经济学方法分析其成本-效果。结果:A组完全缓解39.3%、部分缓解19.5%、总有效率58.8%,成本/效果比为17.19%;B组完全缓解40.1%、部分缓解20.2%、总有效率60.3%,成本/效果比为59.28%,经过检验分析,A组无论药物成本、总成本/效果比均低于B组。结论:A组方案在治疗难治性肾病综合征方面具有成本、效果优势。

OBJECTIVE：To evaluate the efficacy of cyclophosphamide vs.mycophenolate mofetil in the treatment of refractory nephrotic syndrome and evaluate and analyze the cost-effectiveness of the two therapeutic schemes.METHODS：By a randomized double blind method,a total of 36 patients with refractory nephrotic syndrome were randomized to group A（Prednisolone ＋ cyclophosphamide） or group B（Prednisolone ＋ Mycophenolate mofetil dispersible tablets）.The curative efficacy in the two groups was observed and the cost-effectiveness was analyzed by using pharmacoeconomic method.RESULTS：Group A had complete remission rate of 39.3%,partial remission rate of 19.5%,total effective rate of 58.8% and cost / effectiveness ratio of 17.19%;group B had complete remission rate of 40.1%,partial remission rate of 20.2%,total effective rate of 60.3% and cost /effectiveness ratio of 59.28%.Via test and analysis,the costs and the cost /effectiveness ratio in group A were all lower than in group B.CONCLUSION：Therapeutic scheme A is superior to scheme B in terms of cost and effectiveness.